Publications & Presentations

ESMO Virtual Congress, September 19-21, 2020.

• Final Results from ILLUMINATE-204, a Phase 1/2 Trial of Intratumoral Tilsotolimod in Combination with Ipilimumab in PD-1 Inhibitor Refractory Advanced Melanoma
• Phase 1b Trial of ABBV-368 + Tilsotolimod in Combination With Nab-Paclitaxel and/or Budigalimab (ABBV-181) in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

AACR Annual Meeting, Virtual Meeting I, April 27 – 28, 2020

• A Phase 2 Multicenter Study to Evaluate the Efficacy of Tilsotolimod in Combination with Nivolumab and Ipilimumab for Treatment of Microsatellite-Stable Colorectal Cancer (ILLUMINATE-206)
• Tilsotolimod Engages the TLR9 Pathway to Promote Antigen Presentation and Type-I IFN Signaling in Solid Tumors

European Society for Medical Oncology 2019 Congress, Barcelona, Spain, September 27 – October 1, 2019

• Safety, Efficacy and Immune Effects of Intratumoral Tilsotolimod in Patients with Refractory Solid Tumors Updated Preliminary Results from ILLUMINATE-101

AACR 2019 Annual Meeting, Atlanta, GA, March 29 – April 3, 2019

• Activation of Innate and Adaptive Immunity Using Intratumoral Tilsotolimod (IMO-2125) as Monotherapy in Patients with Refractory Solid Tumors: a Phase 1b Study (ILLUMINATE-101)

European Society for Medical Oncology 2018 Congress, Munich, Germany, October 19 – 23, 2018

• The Safety and Efficacy of Intratumoral Injection of the TLR9 Agonist Tilsotolimod (IMO-2125) in Combination with Ipilimumab in Patients with PD-1 inhibitor Refractory Metastatic Melanoma: An Analysis of Efficacy in Injected and Uninjected Lesions.
• A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab Versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma.

International Journal of Oncology, September 2018

• Modulation of the Tumor Microenvironment by Intratumoral Administration of IMO-2125, a Novel TLR9 agonist, for Cancer Immunotherapy.

2018 ASCO Annual Meeting, Chicago, IL, June 1 – 5, 2018

• A Phase 1-2 study to evaluate the safety and efficacy of intratumoral injection of the TLR9 agonist tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory MM

AACR 2018 Annual Meeting, Chicago, IL, April 14 – 18, 2018

• Triple Combination of tilsotolimod, epacadostat, and anti PD 1 antibody demonstrates maximal tumor efficacy and eradicates large established tumors in preclinical models

SITC 2017 Annual Meeting, National Harbor, MD, November 8 – 12, 2017

• TLR9 Agonist Harnesses Innate Immunity Poster Presentation
• IMO-2125 SITC Oral Presentation

ESMO 2017 Congress, Madrid, Spain, September 8 – 12, 2017

• A Phase 1-2 Trial of Intratumoral IMO-2125 (IMO) in Combination with Checkpoint Inhibitors (CPI) in PD-(L)1-refractory Melanoma

Third Annual CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, Mainz, Germany, September 6 – 9, 2017

• Intratumoral IMO-2125 Treatment in Combination with Anti-CTLA-4 mAB Induces Durable Anti-tumor Responses Associated with Tumor-specific Memory in Preclinical Studies

AACR 2017 Annual Meeting, Washington, DC, April 1 – 5, 2017

• Translational evidence of reactivated innate and adaptive immunity with intratumoral IMO-2125 in combination with systemic checkpoint inhibitors from a Phase 1/2 study in patients with anti-PD-1 refractory metastatic melanoma
• Local treatment with novel TLR9 agonist IMO-2125 demonstrates antitumor activity in preclinical models of pancreatic cancer

OPT Boston 2017, Cambridge, MA, March 27 – 29, 2017

• Creating a Beneficial Tumor Microenvironment for Effective Cancer Immunotherapy

2017 ASCO-SITC Clinical Immuno-Oncology Symposium, Orlando, FL, February 23 – 25, 2017

• Intratumoral IMO-2125 a TLR9 Agonist is Active in Combination with Ipilimumab in PD-L(1) Refractory Melanoma

SITC 2016 Annual Meeting, National Harbor, MD, November 9 – 13, 2016

• IMO-2125 – An Investigational Intratumoral Toll-Like Receptor 9 Agonist Modulates the Tumor Microenvironment
• Reactivating the Anti-Tumor Response By Targeting Innate and Adaptive Immunity in a Trial of Intratumoral IMO-2125-oral presentation
• Reactivating the Anti-Tumor Response by Targeting Innate and Adaptive Immunity in a Trial of Intratumoral IMO-2125-poster

AACR 2016 Annual Meeting, New Orleans, LA, April 16 – 20, 2016

• Creating the tumor microenvironment for effective immunotherapy: Anti-tumor activity of intra-tumoral IMO-2125, a TLR9 agonist is further enhanced by inhibition of indoleamine-pyrrole 2,3-dioxygenase (IDO)

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, November 5 – 9, 2015

• Intratumoral Administration of IMO-2125, a Novel TLR9 Agonist, Modulates Tumor Microenvironment and Potentiates Antitumor Activity of Anti-PD-1 mAb in Murine Colon Carcinoma and Melanoma Models

CRI-CIMT-EATI-AACR – The Inaugural International Cancer Immunotherapy Conference, New York, NY, September 16 – 19, 2015

• Intratumoral Administration of IMO-2125, a Novel TLR9 Agonist, Modulates the Tumor Microenvironment and Exerts Systemic Antitumor Activity Alone and in Combination with an Anti-CTLA-4 mAb
• Modulation of Checkpoint Expression in Tumor Microenvironment by Intratumoral Administration of a Novel TLR9 Agonist: Rationale for Combination Therapy